Additionally, understanding the modulation of total antibody expression over a menstrual cycle should inform the assessment of specific antibody responses following a trial of a candidate HIV vaccine, and provide evidence for the standardization of obtaining samples during the menstrual cycle phase

Additionally, understanding the modulation of total antibody expression over a menstrual cycle should inform the assessment of specific antibody responses following a trial of a candidate HIV vaccine, and provide evidence for the standardization of obtaining samples during the menstrual cycle phase. == Supporting Information == (DOCX) (DOCX) (DOCX) == Acknowledgments == We thank Joseph Chilongani, the field teams and participants in Geita, Shinyanga and Kahama, without whom this project would not have been possible. were differences in concentrations among samples from post-ovulation compared to pre-ovulation, notably increased immunoglobulins. Increased prostate-specific antigen, indicative of recent sexual exposure, was correlated with increased IL-6, MCP-1, and SLPI, and decreased GM-CSF and HBD3. The identified signature profiles may show critical in evaluating the potential safety and impact on risk of HIV acquisition of different biomedical intervention strategies. == Introduction == The HIV pandemic continues to expand, with an average of 2.5 million new infections per year [1]. The majority of these new infections are in sub-Saharan Africa, where the epidemic is driven by heterosexual transmission and women make up 60% of the epidemic [1]. Safe, effective, female-controlled HIV prevention methods are urgently needed. Although there have been recent successes with oral pre-exposure prophylaxis, a topical vaginal microbicide and a parenteral vaccine [27], these products have been only partially protective, and the search continues for more robust methods. Investigations following unsuccessful products in Phase 3 clinical trials, especially for products associated with increased rates of HIV contamination such as nonoxynol-9 [8], cellulose sulphate [9], and recombinant Adenovirus-5 HIV vaccines [10], have highlighted the need to better understand immune activation in the female genital tract for early safety assessment. Immune activation in the female genital tract can be caused by contamination, irritation or epithelial trauma, and results in increased or decreased expression of soluble immune proteins [11], and has been shown to result in attraction of cells expressing HIV co-receptors to the cervicovaginal mucosa thereby increasing susceptibility to HIV contamination [8]. Evidence from several trials of ineffective or harmful microbicides has shown that some candidate products can increase concentration of inflammatory immune proteins [8]. Increasingly, clinical studies are measuring soluble immune biomarkers to screen for product-induced mucosal toxicity/irritation in pre-clinical and clinical trials [1217]. The most common soluble proteins evaluated in trials have been interleukin (IL)-1, IL-1, IL-1-receptor antagonist, IL-6, IL-8, tumour necrosis factor (TNF)- and secretory leukocyte peptidase inhibitor (SLPI) [1317]. Soluble immune biomarkers may also be useful for vaccine development; not only providing safety information for mucosal vaccines, but also for parenteral vaccines such as Adenovirus 5 that may increase immune activation at mucosal sites [18,19]. A number of biomedical and behavioural factors can influence expression of immune proteins in the female genital tract [12], Danicopan and more research is needed to understand this background variation for future clinical trials. Two studies have investigated baseline variation in low risk populations appropriate for Phase I clinical trials [20,21]; however, only one study has investigated baseline variation among women at high risk for HIV contamination in sub-Saharan Africa [22]. There is evidence that soluble protein concentrations vary by menstrual cycle phase [23,24], hormonal contraception use [20,25], seminal plasma exposure [26], the composition of the vaginal microbiota [22,27], and the presence of infections, including sexually transmitted infections (STIs) [2830]. In sub-Saharan Africa, the effect of highly Danicopan prevalent vaginal practices, such as intravaginal cleansing, on immune proteins has only been investigated in one study [22,31]. Lastly, many of the studies have focused on pro-inflammatory cytokines and chemokines and, to a lesser extent, growth factors and antimicrobial proteins or peptides. Investigating a wide array of soluble proteins in the female genital tract, including immunoglobulins, may be useful for improving our understanding of their interactions. To address these gaps, we measured the levels of 45 different soluble immune and antimicrobial proteins and peptides in cervicovaginal lavages (CVL) from 100 CDKN2B women participating in an intensive longitudinal sub-study of a larger microbicide feasibility study in North-West Tanzania. Soluble analytes evaluated included pro-inflammatory cytokines, anti-inflammatory cytokines, growth factors, chemokines, antimicrobial proteins and immunoglobulins. We present data from visits without known STIs, and report around the concentrations of these analytes and the association with menstrual cycle, hormonal contraception, seminal plasma exposure, reported intravaginal practices and clinical findings. == Materials and Methods Danicopan == == Ethics Statement == All study procedures were approved by the ethics committees of the London School of Hygiene and Tropical Medicine and the Medical Research Coordinating Committee of the Tanzanian National Institute for Medical Research. All participants received detailed information about the study to ensure that they comprehended why the study was being carried out and what the study included. Informed consent was acquired by personal if literate, or thumb-printed and observed (if illiterate) ahead of their involvement in the analysis. == Study individuals.